Hematologic Cancer News

CAR T-Cell Approvals Leading Landscape of Hematologic Cancers - OncLive



OncLive
 
CAR T-Cell Approvals Leading Landscape of Hematologic Cancers 
OncLive
Adding to the excitement of the FDA's August 2017 monumental approval of tisagenlecleucel (Kymriah) in acute lymphoblastic leukemia (ALL), the agency recently approved the CD19-directed chimeric antigen receptor (CAR) T-cell therapy axicabtagene ...
Israeli-developed breakthrough cancer drug receives FDA approval JNS.org
FDA Approves Second CAR T-Cell Therapy Medscape
FDA Approves Yescarta, First CAR T-Cell Therapy for Lymphoma Managed Care magazine
Technology Networks  -Globes  -FDA.gov  -gilead.com 
all 205 news articles » 


Norman Sharpless sworn in as director of the National Cancer Institute - National Institutes of Health (press release)



National Institutes of Health (press release)
 
Norman Sharpless sworn in as director of the National Cancer Institute 
National Institutes of Health (press release)
As a practicing oncologist at the N.C. Cancer Hospital, the clinical arm of Lineberger, he specialized in the care of patients with hematologic cancers. He is the author of more than 150 original scientific papers, reviews, and book chapters, and is an ...

and more » 


Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized ... - Dove Medical Press



Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized ... 
Dove Medical Press
Purpose: Hematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied. Therefore, we conducted a ...

 


Bloomfield receives Outstanding Clinician-Scientist Award - EurekAlert (press release)



Bloomfield receives Outstanding Clinician-Scientist Award 
EurekAlert (press release)
The award, presented September 20 by the Mayo Clinic's Division of Hematology, recognizes outstanding contributions in the diagnosis and treatment of hematologic cancers, which include leukemias, lymphomas and multiple myeloma. Bloomfield's work ...

 


Signification of Protein p-53 Isoforms in CLL - Cordis News



Signification of Protein p-53 Isoforms in CLL 
Cordis News
Deletion of the P53 gene and mutations in identifying regions of chromosome 17 of hematologic malignancy is important because these mutations have an impact on the clinical management of patients and require an adjustment of adequate therapeutic ...

 


Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia - Business Wire (press release)



Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia 
Business Wire (press release)
SNX-5422 is a chemically unique, orally active Hsp90 inhibitor that has provided durable clinical responses in open label trials in non-small cell lung cancer (NSCLC) and neuroendocrine tumors (NET). The potential of SNX-5422 in hematologic cancers is ...

and more » 


to Host State of the Science Summit?: Hematologic Malignancies - Business Wire (press release)



to Host State of the Science Summit?: Hematologic Malignancies 
Business Wire (press release)
The program will be chaired by Edward Stadtmauer, MD, physician, section chief, hematologic malignancies, at University of Pennsylvania (UPenn) Abramson Cancer Center and the Roseman, Tarte, Harrow, and Shaffer Families' president's distinguished ...

and more » 


Health Literacy Is an Independent Predictor of Cancer Patients' Hospitalizations - Healio



Healio
 
Health Literacy Is an Independent Predictor of Cancer Patients' Hospitalizations 
Healio
Given that standards of care often require patients with hematologic cancers to have long, planned hospitalizations for treatment, a flag variable was created to indicate if a person had a hematologic cancer or a nonhematologic cancer. A flag variable ...

 


Cancer center sees major expansion at Phoenix Children's Hospital - AZCentral.com



AZCentral.com
 
Cancer center sees major expansion at Phoenix Children's Hospital 
AZCentral.com
The number of patients treated at Phoenix Children's Hospital's Center for Cancer and Blood Disorders has more than doubled over the past decade, according to hospital officials. In 2007 there were 8,900 patients treated, compared with 22,420 in 2016 ...

and more » 


Cabozantinib May Be Effective for Acute Myeloid Leukemia - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Cabozantinib May Be Effective for Acute Myeloid Leukemia 
Cancer Therapy Advisor
Cabozantinib may help to evade drug resistance in patients with acute myeloid leukemia (AML), according to research published in Cancer.1. Standard cytotoxic chemotherapy remains the standard treatment for AML, though a large proportion of patients ...